Publications by authors named "C Navarrete"
Background: Vasculogenic therapies explored for the treatment of peripheral artery disease (PAD) have encountered minimal success in clinical trials. Addressing this, B55α, an isoform of protein phosphatase 2A (PP2A), emerges as pivotal in vessel remodeling through activation of hypoxia-inducible factor 1α (HIF-1α). This study delves into the pharmacological profile of VCE-004.
View Article and Find Full Text PDFArticle Synopsis
- VCE-003.2, a derivative of cannabigerol, shows neuroprotective effects in Parkinson's disease models linked to mitochondrial dysfunction and neuroinflammation, now being tested against protein dysregulation associated with the disease.
- Researchers administered an adeno-associated viral vector carrying a mutated α-synuclein gene to mice, causing motor impairments and neuron loss, then treated them with VCE-003.2 to assess its effects.
- Results indicated that VCE-003.2 significantly improved motor performance, preserved neuron integrity, reduced microglia and astrocyte activation in the brain, and influenced gene expression related to immune responses, expanding its potential therapeutic benefits in Parkinson's disease.
High-grade serous ovarian cancer remains a poorly understood disease with a high mortality rate. Although most patients respond to cytotoxic therapies, a majority will experience recurrence. This may be due to a minority of drug-resistant cancer stem-like cells (CSC) that survive chemotherapy and are capable of repopulating heterogeneous tumors.
View Article and Find Full Text PDFCompare two vancomycin dosing strategies in critical patients with methicillin-resistant (MRSA) infections, considering the heterogeneity of the dosing regimens administered and their implications for toxicity and efficacy. Longitudinal retrospective observational study in two patient cohorts (standard dosing vs dosing via Bayesian algorithms). The group of Bayesian algorithms received substantially higher and significantly heterogeneous doses, with an absence of nephrotoxicity.
View Article and Find Full Text PDFBackground: Short-chain fatty acids (SCFAs) are cost-effective carbon sources for an affordable production of lipids. Hexanoic acid, the acid with the longest carbon chain in the SCFAs pool, is produced in anaerobic fermentation of organic residues and its use is very challenging, even inhibiting oleaginous yeasts growth.
Results: In this investigation, an adaptive laboratory evolution (ALE) was performed to improve Yarrowia lipolytica ACA DC 50109 tolerance to high hexanoic acid concentrations.